Navigation Links
Xanodyne Announces Planned President & CEO Succession
Date:5/27/2010

NEWPORT, Ky., May 27 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. is pleased to announce that Natasha Giordano has been named to the position of President and Chief Executive Officer and will be elected to the Company's Board of Directors, succeeding Michael J. Valentino.

The management transition was planned by the Board and follows a year of significant new product and commercial successes under Mr. Valentino's leadership.  In 2009, Xanodyne received FDA approval for Zipsor®, a new treatment option indicated for relief of mild to moderate acute pain in adults.  The Company also received FDA approval for Lysteda™ indicated for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.  Recently, Xanodyne announced that is has tightly focused the strategic direction for the company on the pain management market, and the related sale of Lysteda™ to Ferring Pharmaceuticals.  Xanodyne has a strategic partnership with Ferring for the co-promotion of Zipsor®.

Ms. Giordano most recently served as the company's Chief Operating Officer during this period of unprecedented success.  Ms. Giordano has more than 25 years of experience in the healthcare and pharmaceutical industry and prior to Xanodyne served as President Americas at Cegedim Dendrite, a global sales and marketing solutions and information company specializing in the pharmaceutical industry.  Her depth of experience includes senior leadership positions in general management, marketing, compliance, and sales at major pharmaceutical companies including Pfizer and Parke-Davis.

Ms. Giordano said, "I look forward to working with the Board and management team in continuing to drive toward our vision of being a leader in the pain management category.  We have a proven track record of bringing innovative products to the market, and developing strategic partnerships where desired,  as well as the people, resources and strategy to focus Xanodyne on high growth opportunities within the pain franchise."

Mr. Valentino said, "I am very pleased to be leaving Xanodyne with high caliber talent on the management team, and throughout the organization.  Natasha's knowledge of the industry and her continued strong leadership will sustain the momentum as Xanodyne focuses its growth in pain management. The successful launch of Zipsor®, the portfolio of legacy brands, and strategic divestiture of non-core assets, including Lysteda™, position Xanodyne well for the future."

Rolf Classon, Chairman of the Board said, "We are very pleased with this planned leadership succession.  Mike expanded his Board responsibility to include the CEO role last year with the intent of seeing our drugs through approval and commercialization, and building a team to refine the strategic direction of the business.  The successful partnership between Mike and Natasha allows us a smooth senior management transition as we move forward and execute against our strategic priorities. On behalf of myself and the Board, I'd like to thank Mike for his contributions to the Board and for his stewardship of the Company during this crucial year. "

About Xanodyne Pharmaceuticals, Inc.

Xanodyne, which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused exclusively on pain management. Xanodyne markets a portfolio of products consisting of prescription pain management pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing its pipeline of product candidates targeted at significant potential segments of the pain management market including chronic and severe pain. For more information visit www.Xanodyne.com.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
2. Xanodyne Announces Renewed Focus on Pain Management Market
3. Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
4. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
5. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
6. China Yongxin Pharmaceuticals Announces 1-for-12 Reverse Stock Split
7. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
8. Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
9. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
10. FDA Announces Collaboration With Drugs.com
11. VisEn Announces New ProSense® 750 FAST and Neutrophil Elastase™ 680 FAST Fluorescence Molecular Imaging Agents at European Molecular Imaging Meeting 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... 8, 2017 MACRA replaces the outdated ... for service reimbursement. Black Book Research crowdsource-surveyed 8,845 physician ... 1.       The Market for MIPS Compliance Technology is Booming ... practices with 3 or more clinicians seek to buy ... "Given the magnitude of the changes, the hunt is ...
(Date:5/6/2017)... IRVING, Texas , May 5, 2017   Provista ... 1994 with more than 200,000 customers, today announced Jim ... brings a wealth of executive and business experience to Provista, ... a compounding pharmacy in California . He ... "Jim is a great fit for Provista," says ...
(Date:5/6/2017)... 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), has ... square feet to its Welch Allyn campus. ... to bring more than 100 new jobs to ... has maintained a significant presence for more than 100 ... positions, a large portion of which will be R&D ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability of ... Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to ... ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 ...
(Date:5/23/2017)... ... May 23, 2017 , ... The National Council on ... to announce the organization’s Certified Strength Coach credential has earned accreditation from the ... program validates the competency of qualified candidates for jobs in the Strength and ...
(Date:5/23/2017)... ... 23, 2017 , ... The Gallery of Cosmetic Surgery, founded ... to announce a new treatment option called Vivace Microneedling. This treatment option is ... body through a virtually pain-free, non-surgical treatment. Vivace Microneedling combines a state-of-the-art, best-in-class ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. Allen Huang and ... in Las Vegas, NV, and the importance of treating it immediately. They ... leading care for peri-implantitis, with or without a referral. As experienced periodontists and ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... chat as a standard feature on its secure clinical communication platform. The platform ... to video depending on the type and urgency of a situation. , ...
Breaking Medicine News(10 mins):